STOBOCLO AND OSENVELT: ADVANCING BONE HEALTH WITH DENOSUMAB BIOSIMILARS

Medically Reviewed by Dr. Sony Sherpa (MBBS)

Maintaining strong, healthy bones is vital for overall health, especially as we age or manage certain medical conditions. Bone health disorders such as osteoporosis, bone metastases, and giant cell tumors of bone (GCTB) are prevalent and can significantly impact mobility, quality of life, and long-term outcomes. These conditions often involve excessive bone loss, fragility, or abnormal bone remodeling, necessitating targeted therapies to help preserve bone strength and prevent complications.

Denosumab is a monoclonal antibody (a lab-created protein designed to help the immune system fight disease) that suppresses osteoclast activity (bone breakdown by specialized cells during bone remodeling), which has been a key treatment in managing these conditions for years. Recently, two biosimilars to Denosumab have received FDA approval - Stoboclo and Osenvelt - emerging as new therapeutic options for treating a range of bone-related conditions, offering comparable efficacy at potentially lower costs.

Understanding Denosumab-bmwo

Denosumab-bmwo is a monoclonal antibody that targets RANKL (Receptor Activator of Nuclear factor Kappa-B Ligand), a key protein involved in the formation, function, and survival of osteoclasts - the cells responsible for bone resorption. Denosumab-bmwo binds to RANKL, blocking it from activating its receptor (RANK) on osteoclast surfaces. This inhibition reduces bone resorption and helps increase bone density.

Stoboclo's Primary Use: Osteoporosis and Bone Loss

Osteoporosis is a long-term condition marked by reduced bone mineral density (BMD) and the weakening of bone structure, resulting in increased fragility and a higher risk of fractures, particularly in the hip, spine, and wrist. Often referred to as a “silent disease,” osteoporosis usually develops without noticeable symptoms until a fracture happens, which can severely impact mobility, independence, and overall well-being.

Stoboclo, a biosimilar to Prolia® (denosumab), is used to increase BMD and reduce fracture risk by targeting the underlying cause of excessive bone resorption. By targeting the RANKL pathway, Stoboclo reduces the action of osteoclasts, the cells that break down bone tissue. This action helps preserve bone density and supports the rebuilding of stronger bones over time.

Who Can Benefit from Stoboclo?

Stoboclo is approved for patients at high risk of fractures resulting from low bone density or other factors. Appropriate candidates include:

• Postmenopausal women with osteoporosis.
• Men with osteoporosis who are at high risk of fracture.
• Individuals with glucocorticoid-induced osteoporosis, especially those on long-term corticosteroid therapy.
• Patients undergoing cancer treatments such as androgen deprivation therapy (ADT) for prostate cancer or aromatase inhibitors for breast cancer, which can lead to treatment-induced bone loss.

Dosage and Frequency

The recommended dosage of Stoboclo for osteoporosis and bone loss prevention is:

• 60 mg administered via subcutaneous injection every 6 months.

This twice-yearly dosing offers a convenient alternative to daily or weekly oral medications, improving treatment adherence for many patients.

How Similar Is Stoboclo to Prolia?

Stoboclo has been demonstrated to be highly similar in structure, efficacy, safety, and immunogenicity to its reference product, Prolia®. Regulatory approval was based on comparative analytical and clinical studies, showing that Stoboclo matches Prolia in its ability to increase BMD and reduce the risk of vertebral, nonvertebral, and hip fractures.

Osenvelt's Primary Use: Bone Metastases, Giant Cell Tumor of Bone, and Hypercalcemia of Malignancy

Osenvelt, a biosimilar of Xgeva® (denosumab), is approved for preventing and treating skeletal-related events (SREs) in patients with advanced cancer involving the bones. These include bone metastases from solid tumors, multiple myeloma, giant cell tumors of bone (GCTB), and hypercalcemia of malignancy.

Bone Metastases from Solid Tumors and Multiple Myeloma

When cancer spreads to the bones, as often seen in breast, prostate, lung, kidney, and thyroid cancers, it can lead to serious complications known as skeletal-related events. These include:

• Fractures
• Spinal cord compression
• Need for radiation or surgery on bone

Similarly to Stoboclo, Osenvelt works by inhibiting RANKL, reducing the activity of osteoclasts that are often overstimulated in the presence of bone metastases. This helps to prevent bone destruction, strengthen skeletal integrity, and reduce the risk of painful and disabling SREs.

It is also used in multiple myeloma, a blood cancer that directly affects the bones, leading to lytic lesions and fragility.

Solid Tumors Commonly Treated with Osenvelt:

• Breast cancer
• Prostate cancer
• Lung cancer
• Renal (kidney) cell carcinoma
• Thyroid cancer

Typical Dosage for Bone Metastases:

• 120 mg subcutaneously every 4 weeks, with an additional loading dose of 120 mg on the 8th and 15th day of the first month.

Giant Cell Tumor of Bone (GCTB)

Giant Cell Tumor of Bone (GCTB) is a rare, usually benign, but locally aggressive tumor that can cause extensive bone destruction. Surgery is often the first-line treatment, but in unresectable or surgically complex cases, such as tumors near joints or the spine, medical therapy is preferred.

Osenvelt is indicated for the treatment of giant cell tumor of bone (GCTB) in adults and skeletally mature adolescents in cases where surgical resection is not feasible or would be associated with significant morbidity. By targeting RANKL, Osenvelt inhibits the proliferation of osteoclast-like giant cells, slowing tumor growth and reducing bone loss.

Typical Dosage for GCTB:

• 120 mg subcutaneously every 4 weeks, with loading doses on the 8th and 15th day of the first month, similar to the dosing for bone metastases.

Hypercalcemia of Malignancy

Hypercalcemia of malignancy is a serious complication that occurs in some patients with advanced cancer. When calcium levels rise to dangerous levels, particularly in cases where bisphosphonate therapy is no longer effective, intervention is critical.

Osenvelt is used in these patients to rapidly reduce elevated calcium levels by reducing osteoclast activity and halting excessive calcium release from bones.

Typical Dosage for Hypercalcemia of Malignancy:

• 120 mg subcutaneously every 4 weeks, with loading doses on the 8th and 15th day during the first month, as with other oncology indications.

Advantages of Stoboclo and Osenvelt

Stoboclo and Osenvelt, as biosimilars to Prolia® and Xgeva® respectively, bring with them a wide range of clinical and practical benefits for patients dealing with various bone-related conditions.

Shared Clinical Benefits

These biosimilars maintain the same core efficacy and safety profiles as their reference biologics, offering several therapeutic advantages. Here is a summary of the clinical benefits discussed above:

• Increased Bone Mineral Density (BMD): Particularly with Stoboclo, patients with osteoporosis can expect meaningful gains in BMD, which translates to stronger bones.
• Reduced Risk of Fractures: Both biosimilars contribute to lowering the risk of vertebral, nonvertebral, and hip fractures.
• Preventing Skeletal-Related Events (SREs): In patients with bone metastases, Osenvelt may help prevent serious outcomes like spinal cord compression, bone fractures, and the need for surgical or radiation interventions.
• Effective Management of Giant Cell Tumor of Bone (GCTB): Osenvelt provides a non-surgical approach to managing tumor growth and bone damage in patients with unresectable or high-risk giant cell tumor of bone (GCTB).
• Control of Hypercalcemia of Malignancy: In patients unresponsive to bisphosphonates, Osenvelt effectively lowers elevated calcium levels and prevents complications related to hypercalcemia.

Potential for Cost Savings and Broader Access

One of the notable advantages of Stoboclo and Osenvelt is their potential to reduce treatment costs. As biosimilars, they offer equivalent therapeutic value at a potentially lower price point, which:

• Makes treatment more accessible to a broader patient population, especially in settings with limited healthcare budgets or insurance coverage gaps.
• Supports sustainability in long-term treatment plans, particularly in chronic conditions like osteoporosis or metastatic cancer where lifelong therapy may be needed.

Improved Quality of Life

By preventing fractures, reducing tumor burden, and stabilizing calcium levels, these therapies can:

• Help patients maintain mobility, independence, and daily functioning.
• Reduce hospitalization and emergency care needs due to SREs.
• Allow cancer patients to focus on their primary treatments without the added burden of bone complications.

Additional Advantages Over Reference Products

Stoboclo and Osenvelt may offer non-clinical advantages such as:

• Increased availability: The introduction of biosimilars can improve market supply and minimize treatment delays.
• Healthcare system flexibility: Providers and institutions may benefit from more options for procurement and pricing, allowing better budget management.
• Future innovations: Biosimilar manufacturers may eventually develop prefilled syringes with improved usability or packaging that enhances administration, though the core medication remains the same.

Potential Side Effects and Risks

While Stoboclo and Osenvelt are highly effective treatments for bone-related conditions, like all medications, they may cause side effects. Patients should be informed about both common and serious risks to help them understand the safety profile of these biosimilars.

Common Side Effects

These are generally mild and often improve over time:

• Back pain
• Muscle pain (myalgia)
• Pain in the arms or legs; also referred to as extremity pain
• Joint pain (arthralgia)
• Fatigue
• Constipation
• Nausea

These symptoms usually do not require discontinuation, but patients should monitor them and inform their doctor if they persist or worsen.

Serious but Less Common Side Effects

Though rare, the following adverse effects can be more serious:

• Osteonecrosis of the Jaw (ONJ): This condition involves delayed healing of the jawbone, usually following dental procedures.
  Prevention Tip: Practicing good oral hygiene, scheduling dental checkups before starting treatment, and avoiding invasive dental procedures during treatment can reduce risk.
• Atypical Femoral Fractures: Unusual thigh bone fractures may occur, occasionally with minimal or no trauma. Early signs include persistent thigh or groin pain.
• Hypocalcemia: Denosumab can significantly lower blood calcium levels, especially in patients with kidney problems or vitamin D deficiency.
  Management Tip: Patients are typically advised to take calcium and vitamin D supplements during treatment.

Contraindications and Warnings

Stoboclo and Osenvelt should be avoided or used with caution in the following situations:

• Pre-existing hypocalcemia (must be corrected before starting treatment).
• Hypersensitivity reactions to denosumab or any of its components.
• Pregnancy or planning to become pregnant – Denosumab may harm an unborn baby.
• Breastfeeding – It is not known if denosumab passes into breast milk.

Medications and Interactions to Be Aware Of

There are no major drug interactions, but caution is advised when combining denosumab biosimilars with:

• Bisphosphonates or other bone-modifying agents – may increase the risk of ONJ or hypocalcemia.
• Immunosuppressive drugs – as denosumab is a monoclonal antibody, immune response considerations may apply.
• Loop diuretics – can exacerbate hypocalcemia.

It is important to keep your doctor informed about all your medications and supplements.

When to Seek Medical Attention

Contact your doctor immediately if you experience:

• Jaw pain, swelling, or loose teeth
• Thigh, hip, or groin pain without trauma
• Muscle cramps, numbness, or tingling (signs of low calcium)
• Rash, itching, or trouble breathing (possible allergic reaction)
• New or unusual bone pain

Patient Considerations and Monitoring

Before initiating treatment with Stoboclo or Osenvelt, a careful and comprehensive approach ensures optimal outcomes and minimizes risk.

Initial Assessment

• Before therapy starts, a thorough medical history and physical exam are essential.
• Evaluate for existing hypocalcemia, renal impairment, and dental health issues.
• Discuss any history of fractures, malignancies, or bone-related diseases.

Supplementation

• Proper calcium and vitamin D intake is crucial during treatment. This reduces the risk of hypocalcemia, a known complication.
• Supplementation is typically advised unless contraindicated.

Regular Monitoring

• Serum calcium levels should be monitored, especially within the first two weeks after the initial dose.
• Continued bone mineral density (BMD) assessments and renal function tests may also be required, depending on the indication.
• Adherence to the injection schedule is key to maintaining efficacy and avoiding rebound bone turnover.

Dental Precautions

• Patients should inform their dentist they are receiving denosumab or a biosimilar before undergoing any dental procedure.
• It is advised to complete invasive dental work before starting treatment, when possible.

Latest Research and Developments (Denosumab in General)

While Stoboclo and Osenvelt are approved for specific uses, ongoing research is exploring additional roles for denosumab.

Rheumatoid Arthritis (RA) and Inflammatory Arthropathies

• Some studies have investigated denosumab's RANKL inhibition as a potential way to reduce joint erosion in RA and similar inflammatory conditions.
• While results are promising, these are not approved uses for denosumab or its biosimilars at this time.

Other Investigational Areas

• Bone loss prevention in transplant recipients.
• Use in orthopedic surgery to support bone healing.
• Adjunctive therapy in certain cancers to delay metastasis to bone.

FAQs

Are biosimilars as safe and effective as the original Denosumab products?

Yes. Biosimilars like Stoboclo and Osenvelt undergo rigorous FDA reviews to ensure they are highly similar in safety, potency, and effectiveness to their reference products (Prolia and Xgeva). Clinical data confirm comparable outcomes.

Can one switch between Stoboclo and Osenvelt?

No. These are not interchangeable because they are indicated for different conditions. Even though they are both biosimilars of denosumab, switching should only be done under medical supervision and based on the approved indication.

To search for the best Orthopedics Healthcare Providers in Croatia, Germany, India, Malaysia, Singapore, Spain, Thailand, Turkey, the UAE, UK and the USA, please use the Mya Care search engine.

To search for the best healthcare providers worldwide, please use the Mya Care search engine.

References:

Show All ▼

 

Disclaimer